CRISPR Therapeutics (CRSP)
(Real Time Quote from BATS)
$58.85 USD
+0.98 (1.69%)
Updated Jun 10, 2024 02:10 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Price, Consensus and EPS Surprise
CRSP 58.85 +0.98(1.69%)
Will CRSP be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for CRSP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CRSP
Why Is CRISPR Therapeutics (CRSP) Up 12% Since Last Earnings Report?
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
CRSP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vertex (VRTX) Outperforms Industry on Rapid Pipeline Progress
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
bluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well
Other News for CRSP
Crispr Therapeutics, Futurism-Turning-Commercial, Defies 'Valuation' (Technical Analysis)
The 'Undercovered' Dozen From June 1-6
CRISPR Therapeutics AG (CRSP) Jefferies 2024 Global Healthcare Conference (Transcript)
Crispr Therapeutics call volume above normal and directionally bullish
Intellia Therapeutics Presents Promising In Vivo CRISPR Results